ClinicalTrials.gg
Active, not recruitingNCT07122063Updated Aug 14, 2025

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

A Phase 1/2 interventional study of SYS6045 in Advanced Solid Tumors, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
266
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is the first-in-human (Phase I/II) trial of SYS6045, a multicenter, open-label, dose-escalation and dose-expansion clinical study. It aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of SYS6045 in patients with HER2-positive, expressing, or mutated advanced solid tumors.

Read the detailed description

The trial consists of two parts:Phase I (dose-escalation study): divided into two segments:Dose-escalation phase and PK expansion phase Phase II (dose-expansion study)

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age : ≥18 years.
  2. Performance Status : 0-1.
  3. Tumor Lesion Requirements:

    Dose Escalation Phase: At least one evaluable lesions per v1.1. PK Expansion Phase and Phase II (Dose Expansion Study): At least one per RECIST v1.1.

  4. : ≥3 months.
  5. Adequate Organ Function (confirmed by laboratory tests within 14 days prior to enrollment, without transfusion or hematopoietic growth factor support):

    (ANC) ≥1.5×10⁹/L Count (PLT) ≥100×10⁹/L (Hb) ≥90 g/L Total (TBIL) ≤1.5× (≤3×ULN for participants with liver or hepatocellular carcinoma) /AST ≤2.5×ULN (≤5×ULN for participants with liver metastases or hepatocellular carcinoma) Serum Creatinine (Cr) \<1.5×ULN (APTT) ≤1.5×ULN; International Normalized Ratio (INR) ≤1.5×ULN

  6. (LVEF): ≥50% during screening.
  7. Fertile males or females must agree to use reliable methods (hormonal contraceptives, barrier methods, or abstinence) with their partners during the trial and for ≥7 months after the last dose. Women of must have a negative blood pregnancy test within 7 days before enrollment.
  8. Capable of understanding and voluntarily signing the form Additional Inclusion Criteria for Phase I (Dose Escalation Phase)
  9. or cytologically confirmed advanced/unresectable, or metastatic solid tumors.
  10. -positive, HER2-expressing, or HER2-mutated advanced solid tumors confirmed by a local laboratory (excluding lung cancer; HER2 positivity in lung cancer requires central laboratory confirmation). Prior failure of ≥1 line of standard therapy required.

    Note: Standard therapy is defined as treatment according to established guidelines, consensus, or clinical practice standards. Treatment failure is defined as disease progression or tumor recurrence/metastasis during or after therapy.

    Additional Inclusion Criteria for Phase I (PK Expansion Phase)

  11. Histologically or cytologically confirmed advanced/unresectable, or metastatic solid tumors.
  12. HER2-aberrant, HER2-expressing, or HER2-mutated advanced solid tumors confirmed by a local laboratory (Note: For lung cancer, HER2 genetic alterations may be accepted based on local reports, subject to sponsor review and approval. HER2 IHC/FISH testing for lung cancer requires central laboratory confirmation).

    • Specific Criteria for Breast Cancer Cohort: Histologically or cytologically confirmed advanced/unresectable or metastatic breast cancer.
    • Advanced/unresectable or metastatic colorectal cancer: Histologically or cytologically confirmed, HER2-aberrant (including amplification, overexpression, or mutation).
    • Advanced/unresectable or metastatic non-small cell lung cancer (NSCLC): Histologically or cytologically confirmed, HER2-aberrant).

    Additional Inclusion Criteria for Phase II (Dose Expansion Study).

  13. Documented disease progression or intolerance to the most recent systemic anti-tumor therapy based on radiological and/or pathological evidence.
  14. HER2-positive, HER2-expressing, or HER2-mutated advanced solid tumors confirmed by a local laboratory (Note: For lung cancer, HER2 positivity requires central laboratory confirmation), with prior failure of at least one line of standard therapy.

    • Cohort 2a (HER2-positive breast cancer): Histologically or cytologically confirmed advanced/unresectable or metastatic breast cancer, with prior failure of ≥2 lines of standard therapy.
    • Cohort 2b (HER2-positive breast cancer): Histologically or cytologically confirmed advanced/unresectable or metastatic breast cancer, with prior failure of ≥1 line of standard therapy.
    • Cohort 2c (HER2-positive colorectal cancer): Histologically or cytologically confirmed advanced/unresectable or metastatic colorectal cancer.
    • Cohort 2d (HER2-positive non-small cell lung cancer, NSCLC): Histologically or cytologically confirmed advanced/unresectable or metastatic NSCLC.
    • Cohort 2e (Other solid tumors excluding above types): Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors (excluding breast, colorectal, and NSCLC), with HER2 expressionor HER2 mutation.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with -targeted ADC carrying a topoisomerase I inhibitor payload (e.g., DS-8201) or other TOP1 ADCs (Patients who received such agents in the /adjuvant setting and experienced recurrence ≥12 months after treatment completion may be enrolled)[Applicable to: Phase I PK expansion and Phase II dose expansion studies].
  2. Active neurological conditions, including: Spinal cord compression, clinically active (untreated, symptomatic, or requiring /anticonvulsants for symptom control), carcinomatous meningitis or . Asymptomatic CNS metastases with stable status ≥4 weeks after therapy and on tapering corticosteroids (≤10 mg/day prednisone equivalent) are allowed.
  3. Chronic therapy, including: Long-term immunosuppressants (e.g., cyclosporine),Systemic corticosteroids (>20 mg/day prednisone equivalent), Topical/nasal/inhaled corticosteroids are permitted.
  4. Unresolved toxicities from prior anticancer therapy Not recovered to v5.0 Grade ≤1 or baseline levels(Alopecia, hyperpigmentation, or isolated lab abnormalities deemed non-risky by the investigator).
  5. Recent anticancer treatments (relative to first dose): Immunotherapy/macromolecular agents ≤4 weeks, Cytotoxic chemotherapy/small-molecule therapy ≤2 weeks, Traditional Chinese medicine ≤2 weeks.
  6. Strong inducers/inhibitors or OATP1B1/1B3 inhibitors≤2 weeks before first dose, or Within 5 half-lives (whichever is longer).
  7. Major surgery or invasive procedures≤28 days before first dose Planned tumor resection during the study period.
  8. Known severe allergies to any component of the drug, History of severe to monoclonal antibodies (e.g., trastuzumab) .
  9. Active bacterial, fungal, or viral infections within 14 days prior to the first dose (Defined as requiring intravenous antimicrobial, antifungal, or antiviral therapy). Subjects without clinical manifestations of active infection prior to the first dose who are receiving prophylactic anti-infective treatment may be considered for enrollment.
  10. Uncontrolled serous cavity effusions requiring frequent drainage or medical intervention within 7 days prior to the first dose, includes pleural, peritoneal, or pericardial effusions necessitating additional intervention within 2 weeks post-drainage (excluding acellular cytological testing of exudates)
  11. History of immunodeficiency, including positive antibody test.
  12. Active or infection: Active HBV: HBsAg-positive with HBV DNA>2000 IU/mL,Active HCV: HCV-Ab-positive with HCV RNA> (ULN).
  13. History of non-infectious lung disease /pneumonitis requiring steroid therapy, current interstitial lung disease (ILD)/pneumonitis, or radiographically suspected ILD/pneumonitis during screening.
  14. Severe cardiovascular disease history, including but not limited to:

    • Acute coronary syndrome within 6 months prior to the first dose.
    • Stroke or within 6 months prior to the first dose.
    • Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose.
    • Symptomatic heart failure of class ≥II.
    • Documented history of pulmonary embolism.
    • Prior myocardial infarction.
    • Pericarditis or pericardial effusion requiring clinical intervention.
    • Severe cardiac rhythm/conduction abnormalities (e.g., ventricular arrhythmias requiring intervention, grade II-III atrioventricular block).
    • >450 ms (male) or>470 ms (female), or history/family history of long QT syndrome.
    • (LVEF) \<50%.
    • Uncontrolled hypertension (persistent SBP≥160 mmHg and/or DBP≥100 mmHg despite antihypertensive therapy) or poor adherence to antihypertensive medications
  15. Pregnancy or lactation in female participants.
  16. Presence of other conditions that may interfere with the subject's participation in study procedures, are not in the subject's best interest to participate, or may affect study outcomes: such as history of psychiatric disorders, substance abuse, or any other diseases or conditions.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    SYS6045

    SYS6045,Q3W

    Drug: SYS6045

Interventions

  • DrugSYS6045

    SYS6045, IV Q3W

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: Up to 3 weeks

  2. Incidence and severity of AEs

    Time frame: Up to 3 weeks

  3. Recommended Phase II Dose (RP2D)

    Time frame: Up to 6 months

  4. Objective Response Rate (ORR)

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    Assessed by investigators based on RECIST v1.1 criteria.

    Time frame: Up to 24 months

  2. Disease Control Rate (DCR)

    Time frame: Up to 24 months

  3. Progression-Free Survival (PFS)

    Assessed by investigators based on RECIST v1.1 criteria

    Time frame: Up to 24 months

  4. Incidence and severity of AEs

    Time frame: Up to 24 months

  5. Pharmacokinetic profile(AUC)

    Time frame: Up to 24 months

  6. Rate of anti-SYS6045 antibodies (ADA)

    Time frame: Up to 24 months

  7. Pharmacokinetic profile(Cmax)

    Time frame: Up to 24 months

  8. Pharmacokinetic profile(Tmax)

    Time frame: Up to 24 months

  9. Pharmacokinetic profile(t1/2)

    Time frame: Up to 24 months

  10. Pharmacokinetic profile(CL)

    Time frame: Up to 24 months

  11. Pharmacokinetic profile(MRT)

    Time frame: Up to 24 months

  12. Rate of Neutralizing Antibodies (NAb)(if applicable)

    Time frame: Up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 14, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07122063
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 11, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 14, 2025

Study contacts

Xiu Juan Qu, doctor
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion